Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Phathom Pharmaceuticals, Inc. PHAT

8 fiscal years on record · USD · FY2025 reported · SEC filings only
$175.1M
▲ 216.9% YoY
$-221.2M
$-167.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 175.1M
Revenue, FY2025 · full 8-year series below
Revenue $M Net income $M
FY2025 · Revenue 175.1 · Net income -221.2
100M200M-150M-300M
2018202120242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−126 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -91.4%
-10000%-20000%
201820212025
ROE
FY2021 · ROE -108.0%
-50%-100%
201820212025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -76%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -167.0
-100M-200M
201820212025

Total assetsUSD 259.1M
EquityUSD -438.2M
CashUSD 130.0M
Gross debtUSD 209.1M
Net debtUSD 79.1M
Current ratio1.73×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 8-year record

8 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
PHAT, 8-year financial record
Metric 20252024202320222021202020192018
Revenue $B0.20.10.00.0◌◌◌◌
Operating income $B−0.2−0.3−0.2−0.2−0.1−0.1−0.1−0.0
EBITDA $B−0.2−0.3−0.2−0.2−0.1−0.1−0.1−0.0
Income tax $B0.00.00.00.00.00.00.00.0
Net income $B−0.2−0.3−0.2−0.2−0.1−0.1−0.3−0.0
Free cash flow $B−0.2−0.3−0.1−0.1−0.1−0.1−0.0◌
EPS, diluted $−3.03−5.29−3.93−5.05−3.89−3.88−22.45−0.21
Dividend / sh $◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————
ROE %————−108.0−61.1——
Shares out B0.070.070.060.040.030.030.02◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 36 reconciliationsAUDITED

Reconciled in 8 of the 8 fiscal years we could check. 22 checks were skipped: the balance sheet is not tagged before 2018. 15 checks were skipped: revenue is not tagged before 2022. 11 checks were skipped: EPS is not tagged before 2018.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2018

Share this section

Download image